BAYZF - Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial | Benzinga
Bayer AG (OTC:BAYRY) (OTC:BAYZF) and Asklepios BioPharmaceutical Inc completed an 18-month data collection in the Phase Ib trial for AB-1005 (AAV2-GDNF), an investigational gene therapy for treating patients with Parkinson's disease (PD).
The study met its primary objective, which was to evaluate the safety of a one-time bilateral delivery of AB-1005 directly to the putamen.
Eleven patients were enrolled into two cohorts, Mild stage PD (six patients) and Moderate stage PD (5 patients), ...